reference/30760771

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30760771

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't
endingPage	862
issn	0006-4971 1528-0020
issueIdentifier	3
pageRange	856-862
publicationName	Blood
startingPage	856
bibliographicCitation	Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, Barbui T, Bernasconi C, Dastoli G, Fuga G, Gamba E, Gargantini L, Gattei V, Lauria F, Lazzarino M, Mandelli F, Morra E, Pulsoni A, Ribersani M, Rossi-Ferrini PL, Rupolo M, Tura S, Zagonel V, Zaja F, Zinzani P, Reato G, Foa R. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002 Feb 01;99(3):856–62. doi: 10.1182/blood.v99.3.856. PMID: 11806987.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_93e845a8c00c57c90670976d0a43c5c2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5933-9680 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ad2e311d63ab7d428470421e5b9a2b61 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c2a7cb1b9ea688547729598ece71b930 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c9b89c60d8726eae82cd04c1aabb3b2a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c4de846100060dc3c8be5743fa352e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3d29d6451ef248c01a898208eb926883 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9eae967e92d23d6cd6450ccf8fdfd461 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ceee0a5aed8e5cb82e004e23ce8b1efe http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c38c8600db3c4c288ae3c279dad2d4e7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_328f427d2ac9e96122d047cea35ae275 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8b285205dd518bf36ef69b07a5b6559a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9742a10f96bb35ecc3a315427109c52f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_daefceb851d4d193d7b09c412d6ed4c8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1831e734eeaca49fe93ab0fa48e4ecb7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f76b5bb10ee8e3c2a339b42440882b53 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0f42ffdb4be015a739ce80ec35fa20e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e04ea47ded6ff6a0b6dbdd52c596fd9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_00e33c8c3d30447aab9a704048cf4430 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_79947e4c8fa59c12ae18fe300560e11d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e1d15ed4b2e902c31f42ccd287aa6709 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7088668ee0ef4c8376accf31e08176a2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-3995-8817 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0829-2525 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-3463-2930 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d9ad4d6308f921bc94c25782c796d644 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ca033f26d5093a9d2dc5f7b3321da75c http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7932-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3a98ce8f7097ba1fae1d8d9b6609808a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_359eecc96582df1dc3963d603096e7a3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d3824aa262d518ec2791192ae256d652 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27a1b4ad2065ff2a3c35aae03af92cde
date	2002-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1182/blood.v99.3.856 https://pubmed.ncbi.nlm.nih.gov/11806987
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1243 https://portal.issn.org/resource/ISSN/1528-0020 https://portal.issn.org/resource/ISSN/0006-4971
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma
discusses	http://id.nlm.nih.gov/mesh/M0022676 http://id.nlm.nih.gov/mesh/M0005485 http://id.nlm.nih.gov/mesh/M0017465 http://id.nlm.nih.gov/mesh/M0544940 http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0244307 http://id.nlm.nih.gov/mesh/M0006784
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D008224Q000188 http://id.nlm.nih.gov/mesh/D000911Q000008 http://id.nlm.nih.gov/mesh/D018365Q000175
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D001853 http://id.nlm.nih.gov/mesh/D000971Q000008 http://id.nlm.nih.gov/mesh/D003520Q000008 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D018365Q000188 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D016133 http://id.nlm.nih.gov/mesh/D011379 http://id.nlm.nih.gov/mesh/D005803 http://id.nlm.nih.gov/mesh/D058846 http://id.nlm.nih.gov/mesh/D000911Q000633 http://id.nlm.nih.gov/mesh/D000069283 http://id.nlm.nih.gov/mesh/D004317Q000008 http://id.nlm.nih.gov/mesh/D001773 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D014750Q000008 http://id.nlm.nih.gov/mesh/D008224Q000175 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D011241Q000008 http://id.nlm.nih.gov/mesh/D019254 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D008224Q000401
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10251 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_4f3366af2ce1555e259faab86aad3bef http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8389 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_25c39b14f5f5fb71c1e3563d0a89b452 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_1bf450fbc4b935abf2ef1f826f3802bd

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275

Total number of triples: 92.